ArticleApplied biochemistry and biotechnology2026
Exploring Anticancer Potential of Leucas Aspera Mediated Magnetic Iron Oxide Nanoparticles.
Article in Applied biochemistry and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Iron oxide nanoparticles have gained considerable interest for their potential use in cancer treatment. Our current study, investigates the anti-cancer potential of green-synthesized Leucas aspera nanoparticles against Triple-negative breast cancer, that, belongs to a diverse group of breast cancers and known for its aggressiveness. Research studies on Leucas aspera commonly called as Thumbai, is a source of therapeutically active compounds and have plenty of pharmacological effects. In our study, we have characterized the phytocompounds of leaf extract of Leucas aspera using GC-MS and then, were docked with proteins engaged with apoptosis of breast cancer, such as, BAX, MCL-1 and BCL-2. The extract of L. aspera was phytochemically screened and it demonstrated the existence of bioactive compounds like flavonoids, alkaloids, reducing sugars, saponins, tannins, triterpenoids, glycosides and phenols. The green-synthesis of L. aspera mediated iron oxide nanoparticles (LANPs) was confirmed through characterization, using Fourier Transform Infrared Spectroscopy, Ultraviolet-Visible spectroscopy, Dynamic Light Scattering, Zeta potential, Field Emission Scanning Electron Microscopy and Energy Dispersive X-ray Analysis. In vitro assays, using LANPs showed promising antioxidant and anti-inflammatory activities of 25% and 61% respectively at 100 µg/ml concentration. Furthermore, this study also proved the anti-cancer efficacy of magnetic LANPs against MDA-MB-231 cell lines with a IC50 value of 225.817 µg/ml. The zebra fish toxicity assay, revealed that, the majority of the embryos remained viable without deformations, after exposure to LANPs, indicating their non-toxic nature to normal cells. On further validation of LANPs through appropriate in vivo studies, it can act as an effective targeted therapy against Triple-Negative breast cancer.
Indexed as
Identifiers
41830976What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.